Skip to Content
Developmental Therapeutics Program (DTP)
Last Updated: 04/02/15

TPB Publications

2005 Publications

  1. Eiseman, J. L., J. Lan, T.F. Lagattuta, D.R. Hamburger, E. Joseph, J.M. Covey, et al., 2005. Pharmacokinetics and Pharmacodynamics of 17-Demethoxy 17-(2- dimethylamino)ethyl]amino]geldanamycin (17-DMAG, NSC 707545) in C.B-17 SCID Mice Bbearing MDA-MB-231 Human Breast Cancer Xenografts. Cancer Chemother. Pharmacol., 55, 21-32.
  2. Glaze, E. R., A.L. Lambert, A.C. Smith, J.G. Page, W.D. Johnson, D.L. McCormick, et al., 2005. Preclinical Toxicity of a Geldanamycin Analog, 17-(Dimethylaminoethylamino) -17-demethoxygeldanamycin (17-DMAG), in Rats and Dogs: Potential Clinical Relevance. Cancer Chemother. Pharmacol. 56, 637-647.
  3. Glaze, E.R., A.C. Smith, A.L. Lambert, J.G. Page, W.D. Johnson, D.L. McCormick, A.P. Brown, B.S. Levine, M.J. Egorin and J.E. Tomaszewski, 2005. Preclinical toxicity of a geldanamycin analog, 17-DMAG, in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol, 56, 637-647.
  4. Heller, D., Peggins, J., Nochetto, C., Smith, M., Chiesa, O., and Moulton, K. (2005) LC/MS/MS measurement of gentamicin in bovine plasma, urine, milk, and biopsy samples taken from kidneys of standing animals. Journal of chromatography B, Analytical technologies in the biomedical and life sciences , 821 (1), 22-30.
  5. Holleran, J. L., R.A. Parise, E. Joseph, J.L. Eiseman, J.M. Covey, E.R. Glaze, et al., 2005. Plasma Pharmacokinetics, Oral Bioavailability, and Interspecies Scaling of the DNA Methyltransferase Inhibitor Zebularine. Clin. Cancer Res., 11, 3862-3868.
  6. Jia, L. Tomaszewski, J.E., Noker, P.E., Gorman, G.S., Glaze, E., 2005. Protopopova,M. Simultaneous determination of pharmacokinetic properties of three anti-tubercular ethambutol analogs resulting from combinatorial lead optimization. J. Pharm. Biomed Anal. 37(2), 23-33.
  7. Jia, L. Tomaszewski,J., Hanrahan, C. Coward, L. Noker, P. Gorman, L. Nikonenko, B. Protopopova, M. 2005. Pharmacodynamic and pharmacokinetic characteristics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol. 144, 80-87.
  8. Jia, L. Coward, L. Gorman, L. Noker, P. Tomaszewski, J. 2005. Pharmacoproteomic effects of isoniazid, ethambutol, and N-Geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv. J. Pharmacol. Exp. Ther. 315, 905-911.
  9. Wang, H., Z. Wang, S. Wang, M. Li, L. Nan, J.K. Rhie, et al., 2005. Preclinical Pharmacology of Epothilone D, a Novel Tubulin-stabilizing Antitumor Agent. Cancer Chemother. Pharmacol., 56, 255-260.
  10. Wang, H., M. Li, J.K. Rhie, D.M. Hockenbery, J.M. Covey, R. Zhang, R., et al., 2005. Preclinical Pharmacology of 2-Methoxyantimycin A Compounds as Novel Antitumor Agents. Cancer Chemother. Pharmacol., 56, 291-298.
  11. Xiao, J. J., Y. Huang, Z. Dai, W. Sadée, J. Chen, S. Liu, et al., 2005. Chemoresistance to Depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)- ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6] -tricos-16-ene-3,6,9,22-pentanone] is Mediated by Reversible MDR1 Induction in Human Cancer Cell Lines. J. Pharmacol. Exp. Ther., 314, 467-475.

About the Branch Chief

For information regarding the TPB, please contact Dr. Jerry M. Collins, Associate Director, collinsje@mail.nih.gov